Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Dec 1;120(12):2776-2787.
doi: 10.14309/ajg.0000000000003586. Epub 2025 Jun 10.

Global Prevalence of Celiac Disease in Patients With Rome III and Rome IV Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Mohamed G Shiha  1   2 , Annalisa Schiepatti  3   4 , Francesca Manza  5   6 , Stiliano Maimaris  3   4 , Imran Aziz  1   5 , David S Sanders  1   5
Affiliations
Free article
Meta-Analysis

Global Prevalence of Celiac Disease in Patients With Rome III and Rome IV Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Mohamed G Shiha et al. Am J Gastroenterol. .
Free article

Abstract

Introduction: Irritable bowel syndrome (IBS) and celiac disease (CeD) are common disorders that share overlapping symptoms. In this systematic review and meta-analysis, we aimed to provide up-to-date and comprehensive estimates of the prevalence of CeD in patients with IBS.

Methods: We searched several databases through January 2025 for studies reporting the prevalence of CeD in patients with IBS. Eligible studies used Rome III or Rome IV criteria for IBS diagnosis and used serological screening with tissue transglutaminase, endomysial antibodies, or deamidated gliadin peptide, and/or confirmatory duodenal biopsies for CeD diagnosis. We used random-effects meta-analysis to estimate the pooled prevalence of seropositive and biopsy-proven CeD with 95% confidence intervals (CI). We calculated pooled odds ratios to compare the likelihood of CeD between patients with IBS and controls.

Results: A total of 29 studies comprising 7,209 patients with IBS were included. The pooled seroprevalence of CeD in patients with IBS was 6% (95% CI, 5%-8%), and the pooled prevalence of biopsy-proven CeD was 2% (95% CI, 2%-3%). A significant proportion of seropositive patients (15%; 95% CI, 6%-24%) did not undergo endoscopy and biopsy. Patients with IBS had significantly higher odds of a positive serology than controls (odds ratio 4.42; 95% CI, 2.82-6.92). The odds of CeD were similar across genders and IBS subtypes. There was a limited number of studies from Europe and no studies from the United States.

Discussion: CeD is highly prevalent in patients with IBS, according to the Rome III and Rome IV criteria. A positive diagnosis of IBS should not be made without excluding CeD.

Keywords: Celiac disease; duodenal biopsy; irritable bowel syndrome; serology.

PubMed Disclaimer

References

    1. Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:908–17.
    1. Drossman DA. The Rome criteria process: Diagnosis and legitimization of irritable bowel syndrome. Am J Gastroenterol 1999;94(10):2803–7.
    1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150(6):1393–407.e5.
    1. Shiha MG, Chetcuti Zammit S, Elli L, et al. Updates in the diagnosis and management of coeliac disease. Best Pract Res Clin Gastroenterol 2023;64-65:101843.
    1. Malamut G, Cellier C. Complications of coeliac disease. Best Pract Res Clin Gastroenterol 2015;29(3):451–8.

MeSH terms